Abbott Laboratories (NYSE:ABT) Releases Earnings Results, Beats Expectations By $0.03 EPS

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Thursday. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03, FiscalAI reports. The business had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories updated its Q3 2026 guidance to 1.380-1.46 EPS and its FY 2026 guidance to 5.450-5.60 EPS.

Here are the key takeaways from Abbott Laboratories’ conference call:

• Abbott beat Q2 expectations with comparable sales growth of 4.8% and adjusted EPS of $1.31, while reaffirming full-year sales guidance and raising its EPS outlook to $5.45-$5.60.
• The company highlighted a strong pipeline and near-term launch cadence, including TECTONIC, Amulet 360, Libre Duo, and TactiFlex Duo, with multiple additional trials set to start in Q4.
• Nutrition trends improved meaningfully, with sales up sequentially and U.S. Ensure consumption rebounding double digits; management said WIC wins, pricing actions, and new products support a 2%-4% growth range.
• Medical devices remain a key growth driver, led by 8.5% overall device growth, accelerating electrophysiology launches, strong international traction, and continued CGM momentum above $2 billion in quarterly sales.
• Management said some areas still need work, especially U.S. structural heart and the timing of reimbursement expansions for diabetes care, but it expects second-half acceleration and improving trends into 2027.

Abbott Laboratories Trading Up 1.9%

ABT opened at $100.71 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business has a 50 day simple moving average of $89.89 and a two-hundred day simple moving average of $102.17. The firm has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.70 and a beta of 0.61.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Leerink Partners cut their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Benchmark lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Oppenheimer reduced their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.61.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ABT. Intesa Sanpaolo Wealth Management purchased a new position in Abbott Laboratories in the 4th quarter worth approximately $29,000. Turning Point Benefit Group Inc. bought a new position in shares of Abbott Laboratories during the third quarter valued at $39,000. SWAN Capital LLC raised its position in Abbott Laboratories by 53.1% in the 4th quarter. SWAN Capital LLC now owns 300 shares of the healthcare product maker’s stock worth $38,000 after buying an additional 104 shares during the last quarter. Wealth Watch Advisors INC boosted its holdings in shares of Abbott Laboratories by 121.6% during the 4th quarter. Wealth Watch Advisors INC now owns 359 shares of the healthcare product maker’s stock valued at $45,000 after acquiring an additional 197 shares during the last quarter. Finally, Swiss RE Ltd. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $49,000. Institutional investors own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.